



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Jackson, et al.

Application No.: 10/828,394


Filed: 4/19/2004

Title: Method for Treatment of Cancerous  
Angiogenic Disorders

Attorney Docket No.: UBC.P-033

Group Art Unit: 1614

Examiner:



Assistant Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants request that the references listed on form PTO 1449, which is attached, be made of record in the US Patent and Trademark Office in the file relating to the above-captioned application. Copies of the listed non-U.S. references are enclosed.

No fees are believed due for this IDS since we have not received an action on the merits. The Commissioner is authorized to charge any fees due in connection with this paper or credit any overpayment to Deposit Account No. 15-0610.

Respectfully Submitted,

*Marina T. Larson*  
Marina T. Larson, Ph.D  
Attorney/Agent for Applicant(s)  
Reg. No. 32038

(970) 468 6600

Cert. Under 37 CFR 1.8  
This paper and the attachments named herein are being  
deposited with the United States Postal Service  
with sufficient postage as first class mail and addressed to  
Commissioner for Patents, P.O. Box 1450,  
Alexandria, Virginia 22313-1450 on

MAR - 4 2005

Name Lianna McCarthy

Signature Lianna McCarthy



PTO/SB/08a (08-03)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

10

6

Application Number: 10/288,884

Application Number	10/828,394
Filing Date	4/19/2004
First Named Inventor	Jackson et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	UBC.P-033

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO 00/34469	06-15-2000	The Research Foundation of		
		WO 00/49937	08-31-2000	The University of British		
		WO 01/46455 A2	06-28-2001	Yale University		
		WO 02/22635 A1	03-21-2002	ISIS Pharmaceuticals, Inc.		
		WO 03/062421 A1	07-31-2003	The University of British		
		WO 03/072591 A1	09-04-2003	The University of British		
		WO 2004/018675 A1	03-04-2004	The University of British		
		WO 2004/018676 A2	03-04-2004	The University of British		

Examiner Signature \_\_\_\_\_ Date Considered \_\_\_\_\_

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of US PTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

6

**Complete If Known**

Application Number	10/828,394
Filing Date	4/19/2004
First Named Inventor	Jackson et al.
Art Unit	1614
Examiner Name	

Attorney Docket Number UBC.P-033

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		AGRAWAL ET AL., Antisense Therapeutics: is it as simple as complementary base recognition, Molecular Medicine Today, 2000, Page(s) 72-81, Volume 6, Publisher: Elsevier Science Ltd.	
		AOKI ET AL., RNA Interference may be more potent than antisense RNA in human cancer cell lines, Clinical and Experimental Pharmacology and Physiology, 2003, Page(s) 96-102	
		BENNER ET AL., Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies, Journal of Pharmacological and Toxicological Methods, 1997, Page(s) 229-235, Publisher: Elsevier Science Inc.	
		BORAL ET AL., Clinical evaluation of biologically targeted drugs: obstacles and opportunities, Cancer Chemother Pharmacol, 1998, Page(s) S3-S21, Publisher: Springer-Verlag	
		ANDREA D. BRANCH, A good antisense molecule is hard to find, TIBS, 1998, Page(s) 45-50, Publisher: Elsevier Science Ltd.	
		STEVEN BREM, MD, Angiogenesis and Cancer Control: From Concept to Therapeutic Trial, Cancer Control Journal, 1999, Volume 6, Number 5, Publisher: H. Lee Moffitt Cancer Center & Research Institute	
		BRUCHOVSKY ET AL., Control of Tumor Progression by Maintenance of Apoptosis, www.prostatepointers.org, 1996, Publisher: Wiley-Liss, Inc.	
		BUTTYAN ET AL., Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death, Molecular and Cellular Biology, 1989, Page(s) 3473-3481, Volume 9, Number 8, Publisher: American Society for Microbiology	
		COX ET AL., Angiogenesis and non-small cell lung cancer, Lung Cancer, 2000, Page(s) 81-100, Publisher: Elsevier	
		CROOKE ET AL., Basic Principles of Antisense Therapeutics, Antisense Research and Application, 2004, Page(s) 1-50, Chapter 1, Publisher: Springer	
		DARBY ET AL., Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity, Exp Nephrol, 1995, Page(s) 234-239, Publisher: S. Karger AG	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DEMA 1000 Substitute for form 1449B/PTO

				<b>Complete if Known</b>	
				Application Number	10/828,394
				Filing Date	4/19/2004
				First Named Inventor	Jackson et al.
				Art Unit	1614
				Examiner Name	
Sheet	3	of	6	Attorney Docket Number	UBC.P-033

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		DIEMER ET AL., Expression of Porcine Complement Cytolysis Inhibitor mRNA in Cultured Aortic Smooth Muscle Cells, The Journal of Biological Chemistry, March 15, 1992, Page(s) 5257-5264, Volume 207, Number 8, Publisher: The American Society for Biochemistry and Molecular Biology, Inc.		
		GENTA, New Data Reaffirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment, www.genta.com, 2001		
		GLEAVE ET AL., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2, Urology, , Page(s) 39-49, Volume 58		
		GLEAVE ET AL., Antisense therapy: Current status in prostate cancer and other malignancies, Cancer and Metastasis Reviews, , Page(s) 79-92, Volume 21		
		GLEAVE ET AL., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- , Investigational New Drugs, , Page(s) 145-158, Volume 20, Number 2, Publisher: XP 009021411		
		GLEAVE ET AL., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced prostate Cancer, Current Drug Targets, , Page(s) 209-221, Volume 4		
		JEN ET AL., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells 2000, 2000, Page(s) 307-319, Volume 18		
		JONES ET AL., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, , Page(s) 427-431, Volume 34, Publisher: XP002262319		
		KADOMATSU ET AL., Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate, Cancer Res, April 1, 1993, Page(s) 1480-1483, Volume 53, Number 7		
		KIRBY ET AL., Bartonella-associated endothelial proliferation depends on inhibition of apoptosis, PNAS, April 2, 2002, Page(s) 4656-4661, Volume 99, Number 7		
		KYPRIANOU ET AL., bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate , International Journal of Cancer, January 27, 1997, Page(s) 341-348, Volume 70, Number 3		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



MAR 8 2005

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/828,394
(Use as many sheets as necessary)				Filing Date	4/19/2004
				First Named Inventor	Jackson et al.
				Art Unit	1614
				Examiner Name	
Sheet	4	of	6	Attorney Docket Number	UBC.P-033


<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		LEE ET AL., In Vitro Models of Prostate Apoptosis: Clusterin as an Antiapoptotic Mediator, The Prostate Supplement, 2000, Page(s) 21-24, Volume 9, Publisher: Wiley-Liss, Inc.		
		MILLAR ET AL., Localization of mRNAs by in-situ hybridization to the residual body at stages IX-X of the cycle of the rat seminiferous , International Journal of Andrology, 1994, Page(s) 149-160, Volume 17		
		MILLIS ET AL., Clusterin Regulates Vascular Smooth Muscle Cell Nodule Formation and Migration, Journal of Cellular Physiology, 2001, Page(s) 210-219, Volume 186, Publisher: Wiley-Liss, Inc.		
		MILNER ET AL., Selecting effective antisense reagents on combinatorial oligonucleotide arrays, Nature Biotechnology, 1997, Page(s) 537-541, Volume 15		
		MIYAKE ET AL., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both..., Clinical Cancer Research, 5/1/2000, Page(s) 1655-1663, Volume 6		
		MIYAKE ET AL., Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in.., Cancer Research, 1/1/2000, Page(s) 170-176, Volume 60		
		MIYAKE ET AL., Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide...., Clinical Cancer Research, , Page(s) 4245-4252, Volume 7		
		MIYAKE ET AL., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic .., International Journal of Urology, , Page(s) 337-349, Volume 8, Number 7, Publisher: XP002262321		
		NÖR ET AL., Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice, Laboratory Investigation, 2001, Page(s) 453-463, Volume 81, Number 4		
		NÖR ET AL., Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth, March 1, 2001, Page(s) 2183-2188, Volume 61		
		OPALINSKA ET AL., Nucleic-acid therapeutics: Basic principles and recent applications, Nature Reviews, 2002, Page(s) 503-514, Volume 1		

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Approved for use through 06/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/828,394
(Use as many sheets as necessary)				Filing Date	4/19/2004
Sheet	5	of	6	First Named Inventor	Jackson et al.
				Art Unit	1614
				Examiner Name	
				Attorney Docket Number	UBC.P-033

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		ROSENBERG ET AL., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., , Page(s) 633-645, Volume 27, Number 7, Publisher: XP001002844		
		SENSIBAR ET AL., Prevention of Cell Death Induced by Tumor Necrosis Factor $\alpha$ in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 , Cancer Research, , Page(s) 2431-2437, Volume 55, Publisher: American Association for Cancer Research, Baltimore, MD, US, XP002930082		
		TRAN ET AL., A role for survivin in chemoresistance of endothelial cells mediated by VEGF, PNAS, April 2, 2002, Page(s) 4349-4354, Volume 99, Number 7		
		TROUGAKOS ET AL., Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces , Cancer Research, March 1, 2004, Page(s) 1834-1842, Volume 64		
		VICKERS ET AL., Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents, The Journal of Biological Chemistry, February 28, 2003, Page(s) 7103-7118, Volume 278, Number 9		
		WILSON ET AL., Clusterin is a secreted mammalian chaperone, Trends in Biological Sciences, 3/1/2000, Page(s) 95-98, Volume 25, Number 3, Publisher: Elsevier Science, Ltd. XP004202536		
		WONG ET AL., Molecular characterization of human TRPM-2-clusterin, a gene associated with sperm maturation, apoptosis and neuro..., European Journal of Biochemistry, , Page(s) 917-925, Volume 227, Number 3, Publisher: XP 001146404		
		WRIGHT ET AL., A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate , Experimental Cell Research, January 10, 1996, Page(s) 54-60, Volume 222, Number 1		
		YANG ET AL., Nuclear clusterin/XIP8, an $\alpha$ -ray-induced Ku70-binding protein that signals cell death, PNAS, May 23, 2000, Page(s) 5907-5912, Volume 97, Number11		
		ZANGEMEISTER-WITTKE ET AL., A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces ....., Clinical Cancer Research, 6/1/2000, Page(s) 2547-2555, Volume 6		
		ZELLWEGER ET AL., Antitumor Activity of Antisense Clusterin Oligonucleotides is Improved in Vitro and in Vivo by Incorporation of....., The Journal of Pharmacology and Experimental, 5/11/2001, Page(s) 934-940, Volume 298, Number 3		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Mar 8 7 2005

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

Approved for use through 08/31/2008. GPO 08-1 0001 0001

Substitute for form 1449B/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Substitute for form 1449B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/828,394
(Use as many sheets as necessary)		Filing Date	4/19/2004
		First Named Inventor	Jackson et al.
		Art Unit	1614
		Examiner Name	
Sheet	6	of	6
		Attorney Docket Number	UBC.P-033

## NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.